HealthCare Royalty Partners is a royalty acquisition company focused on commercial or near-commercial stage biopharmaceutical products. self-described.

HealthCare Royalty Partners

Oberland Capital is a healthcare focused investment firm that provides non-dilutive capital to life sciences companies. The firm specializes in structured finance and royalty monetization, offering innovative financing solutions tailored to the unique needs of healthcare companies.

Jean-Pierre Naegeli

Oberland Capital

HealthCare Royalty | 1,961 followers on LinkedIn. Advancing Biopharmaceutical Innovation with Creative Capital Solutions | HealthCare Royalty (&quot;HCRx&quot;) is a leading royalty acquisition company focused on commercial or near-commercial stage biopharmaceutical products. HCRx has invested $5+ billion in more than 85 biopharma products since inception and has offices in Stamford (CT), San Francisco, Boston and London.  The HCRx team consists of 33 individuals (including our Senior Advisors), including former pharmaceutical executives, scientists, physicians, bankers, research analysts and consultants.

Frank Armstrong

Chief Scientific Officer at HealthCare Royalty

Shin Kang

Chief Executive Officer at Memgen

Greg Brown

Chief Medical Officer at HealthCare Royalty

Warren Cooper

HealthCare Royalty

HealthCare Royalty and Blue Owl Announce $250M Debt Financing with TG Therapeutics https://lnkd.in/e2tjDbq7

Valinor Pharma Announces Acquisition by Grünenthal with a Total Deal Value of Approximately $250 Million

Grünenthal acquires US-company Valinor Pharma and becomes global owner of Movantik®

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA’s Profit Share Payments

We are thrilled to share insights from the recent roundtable discussion hosted by DNB and Back Bay Life Science Advisors. On May 7th, 2024, industry leaders Clarke Futch, Chairman and CEO of HealthCare Royalty (HCRx), and Chris Posner, President and CEO of Cara Therapeutics, engaged in a thought-provoking discussion on alternative financing in healthcare. Moderated by Jonathan Gertler of Back Bay Life Science Advisors, the forum also featured Anne Grabe, Global Head of Healthcare Banking, DNB, and Patrik Ling, Senior Analyst, DNB. This diverse group of experts delved into innovative financing strategies that are shaping the future of healthcare.

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029

Zevra Therapeutics Refinances Existing Debt With Up To $100M In Committed Capital Under New Credit Facility

Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million https://lnkd.in/ef5Ar6EC

Thank you to everyone who joined us in the Dominican Republic at our 14th Annual Senior Advisor Board Offsite. Lots of interesting and insightful sessions in a beautiful setting.

Liquidia Corporation Announces $100 Million in New Financings https://lnkd.in/ez-rBm6z

Metric
Company Name	HealthCare Royalty Partners	Oberland Capital
Symbol
MSH ID	COM:HCRX	COM:OBERLANDCAPITAL
Market	PRIVATE	PRIVATE
Sector	Financial Services & Finance	Financial Services & Finance
Industry	Healthcare & Health Services	Healthcare
Country	US	US
Stage	Debt Financing
Employee Count		23
Website	hcrx.com	oberlandcapital.com
LinkedIn	healthcare-royalty	oberland-capital
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital	680M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

HCRX

COM:HCRX

HealthCare Royalty Partners

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue